DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.14
+0.73%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -4.4%
- EBIT
- -5.9%
- EPS
- -5.4%
- Free cash flow
- -8.6%
- Operating cash flow
- -8.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -35.5%
- EPS
- -22.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -41.2%
- EBIT
- -27.4%
- Net income
- -40.7%
- EPS
- -38.6%
- Free cash flow
- -25.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026